[ad_1]
In patients receiving nusinersen (Spinraza) for the treatment of SMA muscular disease (spinal muscular atrophy), symptoms of accumulation of cerebral fluid may develop. This is reported by the Medicines Evaluation Board (CGB).
Five patients have been reported worldwide with this side effect since the introduction of this drug, writes Biogen. Two of them received a shunt to regulate pressure in the brain.
Nusinersen works by helping the body produce a protein that is deficient in people with spinal muscular atrophy. This increases muscle strength.
For about eighty very young children with ADS, the drug – very expensive – comes into effect August 1 in basic packaging. Minister Bruno Bruins (Medical Care) recently signed an agreement with Biogen, making an "acceptable price" possible. The exact amount agreed upon is unknown.
See also:
Source link
